Abstract:Magnetic iron oxide nanoparticles (IONP) are promising theranostic platforms for cancer imaging and treatment. However, delivery of nanoparticles with conventional sizes to intracranial tumors is challenging due to the physiological and biological barriers in the central nervous system. Since advanced glioblastoma (GBM) is highly angiogenic with leaky tumor blood vessels, sub-5 nm ultrafine IONP (uIONP) may preferentially extravasate from the tumor vasculature to exert blood–brain-barrier/blood–tumor-barrier crossing and intratumoral accumulation. Herein, we demonstrate that the renally clearable sub-5 nm oligosaccharide-coated uIONP can efficiently reach intracranial brain tumors in the orthotopic mouse model of GBM after intravenous (i.v.) injection, enabling the visualization of tumors by T 1-weighted magnetic resonance imaging (MRI). Delivery and intratumoral distribution of uIONP are primarily promoted by the enhanced permeability and retention (EPR) effect due to the sub-5 nm core size. uIONP exhibited time-dependent brain tumor uptake with bright T 1-enhanced MRI contrast gradually peaking at 40–60 min after injection. uIONP were compartmentalized in tumor blood vessels at early time points (∼20 min), before extravasating and subsequently reaching different areas of tumors (∼60 min) but not in the normal brain tissues. The size advantage of sub-5 nm uIONP in delivery and intratumoral distribution was examined by the comparison between co-injected uIONP and IONP (10 nm core size) labeled with different fluorescent dyes, using MRI, near-infrared (NIR) imaging, fluorescence microscopy, and immunohistochemistry analysis. NIR dye NIR830-labeled uIONP exhibited a sixfold higher penetration and retention in the intracranial tumor than the fluorescein isothiocyanate-labeled IONP with a 10-nm core diameter at 1 h after co-injection. Together, our results demonstrate the sub-5 nm size advantage in delivery of renally clearable nanotheranostics, such as uIONP, for molecular imaging and treatment of brain tumors.

Overcoming The Physiopathologic Barriers: Nanoprobes-Mediated Intracranial Glioma Imaging

Biomimetic Multifunctional Persistent Luminescence Nanoprobes for Long-Term Near-Infrared Imaging and Therapy of Cerebral and Cerebellar Gliomas

Nanoprobes Visualizing Gliomas by Crossing the Blood Brain Tumor Barrier

Construction of nanomaterials as contrast agents or probes for glioma imaging

Biomimetic Nanocomposites for Glioma Imaging and Therapy

Glioma nanomedicine: Design, fabrication and theranostic application

Image‐guided Diagnosis and Treatment of Glioblastoma

Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions

Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma.

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature

Nanotechnology as a new strategy for the diagnosis and treatment of gliomas

Advances in Magnetic Resonance Imaging Contrast Agents for Glioblastoma-Targeting Theranostics

Functional nanoparticles in targeting glioma diagnosis and therapies.

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma

Dual-targeting upconversion nanoprobes across the blood-brain barrier for magnetic resonance/fluorescence imaging of intracranial glioblastoma.

Applications of nanoparticles for brain cancer imaging and therapy.

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates

Recent patents on imaging nanoprobes for brain tumor diagnosis and therapy.

Strategies to Overcome/penetrate the BBB for Systemic Nanoparticle Delivery to the Brain/brain Tumor.

Brain Tumor Imaging and Delivery of Sub-5 nm Magnetic Iron Oxide Nanoparticles in an Orthotopic Murine Model of Glioblastoma